Dermatologic Complications | Regenecare® Wound Gel in Treating Rash in Patients Receiving Cetuximab or Other Epidermal Growth Factor Receptor Inhibitor Therapy for Cancer
Dermatologic Complications research study
What is the primary objective of this study?
RATIONALE: Regenecare® wound gel may help relieve pain and itching in patients who develop an acne-like rash while undergoing treatment with cetuximab or another epidermal growth factor receptor inhibitor for cancer. PURPOSE: This clinical trial is studying how well Regenecare® wound gel works in treating rash in patients receiving cetuximab or another epidermal growth factor receptor inhibitor therapy for cancer.
Who is eligible to participate?
DISEASE CHARACTERISTICS: - Diagnosis of cancer - Starting treatment with cetuximab or other EGFR inhibitor (e.g., erlotinib hydrochloride) on another clinical trial PATIENT CHARACTERISTICS: - Not pregnant or nursing - No known history of hypersensitivity to amine-type local anesthetics or to other components of MPM Regenecare® wound gel - No other concurrent, serious skin disorders (i.e., scleroderma or psoriasis) that would interfere with assessment of EGFR inhibitor-induced rash PRIOR CONCURRENT THERAPY: - See Disease Characteristics - No other concurrent topical facial creams or lotions
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Unspecified Adult Solid Tumor, Protocol Specific
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Dietary Supplement:collagen/aloe vera/vitamin E/lidocaine topical hydrogel
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Start Date: July 2006
Primary Outcome: Efficacy of Regenecare® wound gel, in terms of alleviating pain and itching
Secondary Outcome: Efficacy of Regenecare® wound gel, in terms of reducing severity, redness, and appearance of rash
Study sponsors, principal investigator, and references
Principal Investigator: Mark F. Kozloff, MD
Lead Sponsor: Ingalls Memorial Hospital